Tag Archives: Hugh Herr

Going blind when your neural implant company flirts with bankruptcy (long read)

This story got me to thinking about what happens when any kind of implant company (pacemaker, deep brain stimulator, etc.) goes bankrupt or is acquired by another company with a different business model.

As I worked on this piece, more issues were raised and the scope expanded to include prosthetics along with implants while the focus narrowed to neuro as in, neural implants and neuroprosthetics. At the same time, I found salient examples for this posting in other medical advances such as gene editing.

In sum, all references to implants and prosthetics are to neural devices and some issues are illustrated with salient examples from other medical advances (specifically, gene editing).

Definitions (for those who find them useful)

The US Food and Drug Administration defines implants and prosthetics,

Medical implants are devices or tissues that are placed inside or on the surface of the body. Many implants are prosthetics, intended to replace missing body parts. Other implants deliver medication, monitor body functions, or provide support to organs and tissues.

As for what constitutes a neural implant/neuroprosthetic, there’s this from Emily Waltz’s January 20, 2020 article (How Do Neural Implants Work? Neural implants are used for deep brain stimulation, vagus nerve stimulation, and mind-controlled prostheses) for the Institute of Electrical and Electronics Engineers (IEEE) Spectrum magazine,

A neural implant, then, is a device—typically an electrode of some kind—that’s inserted into the body, comes into contact with tissues that contain neurons, and interacts with those neurons in some way.

Now, let’s start with the recent near bankruptcy of a retinal implant company.

The company goes bust (more or less)

From a February 25, 2022 Science Friday (a National Public Radio program) posting/audio file, Note: Links have been removed,

Barbara Campbell was walking through a New York City subway station during rush hour when her world abruptly went dark. For four years, Campbell had been using a high-tech implant in her left eye that gave her a crude kind of bionic vision, partially compensating for the genetic disease that had rendered her completely blind in her 30s. “I remember exactly where I was: I was switching from the 6 train to the F train,” Campbell tells IEEE Spectrum. “I was about to go down the stairs, and all of a sudden I heard a little ‘beep, beep, beep’ sound.’”

It wasn’t her phone battery running out. It was her Argus II retinal implant system powering down. The patches of light and dark that she’d been able to see with the implant’s help vanished.

Terry Byland is the only person to have received this kind of implant in both eyes. He got the first-generation Argus I implant, made by the company Second Sight Medical Products, in his right eye in 2004, and the subsequent Argus II implant in his left 11 years later. He helped the company test the technology, spoke to the press movingly about his experiences, and even met Stevie Wonder at a conference. “[I] went from being just a person that was doing the testing to being a spokesman,” he remembers.

Yet in 2020, Byland had to find out secondhand that the company had abandoned the technology and was on the verge of going bankrupt. While his two-implant system is still working, he doesn’t know how long that will be the case. “As long as nothing goes wrong, I’m fine,” he says. “But if something does go wrong with it, well, I’m screwed. Because there’s no way of getting it fixed.”

Science Friday and the IEEE [Institute of Electrical and Electronics Engineers] Spectrum magazine collaborated to produce this story. You’ll find the audio files and the transcript of interviews with the authors and one of the implant patients in this February 25, 2022 Science Friday (a National Public Radio program) posting.

Here’s more from the February 15, 2022 IEEE Spectrum article by Eliza Strickland and Mark Harris,

Ross Doerr, another Second Sight patient, doesn’t mince words: “It is fantastic technology and a lousy company,” he says. He received an implant in one eye in 2019 and remembers seeing the shining lights of Christmas trees that holiday season. He was thrilled to learn in early 2020 that he was eligible for software upgrades that could further improve his vision. Yet in the early months of the COVID-19 pandemic, he heard troubling rumors about the company and called his Second Sight vision-rehab therapist. “She said, ‘Well, funny you should call. We all just got laid off,’ ” he remembers. She said, ‘By the way, you’re not getting your upgrades.’ ”

These three patients, and more than 350 other blind people around the world with Second Sight’s implants in their eyes, find themselves in a world in which the technology that transformed their lives is just another obsolete gadget. One technical hiccup, one broken wire, and they lose their artificial vision, possibly forever. To add injury to insult: A defunct Argus system in the eye could cause medical complications or interfere with procedures such as MRI scans, and it could be painful or expensive to remove.

The writers included some information about what happened to the business, from the February 15, 2022 IEEE Spectrum article, Note: Links have been removed,

After Second Sight discontinued its retinal implant in 2019 and nearly went out of business in 2020, a public offering in June 2021 raised US $57.5 million at $5 per share. The company promised to focus on its ongoing clinical trial of a brain implant, called Orion, that also provides artificial vision. But its stock price plunged to around $1.50, and in February 2022, just before this article was published, the company announced a proposed merger with an early-stage biopharmaceutical company called Nano Precision Medical (NPM). None of Second Sight’s executives will be on the leadership team of the new company, which will focus on developing NPM’s novel implant for drug delivery.The company’s current leadership declined to be interviewed for this article but did provide an emailed statement prior to the merger announcement. It said, in part: “We are a recognized global leader in neuromodulation devices for blindness and are committed to developing new technologies to treat the broadest population of sight-impaired individuals.”

It’s unclear what Second Sight’s proposed merger means for Argus patients. The day after the merger was announced, Adam Mendelsohn, CEO of Nano Precision Medical, told Spectrum that he doesn’t yet know what contractual obligations the combined company will have to Argus and Orion patients. But, he says, NPM will try to do what’s “right from an ethical perspective.” The past, he added in an email, is “simply not relevant to the new future.”

There may be some alternatives, from the February 15, 2022 IEEE Spectrum article (Note: Links have been removed),

Second Sight may have given up on its retinal implant, but other companies still see a need—and a market—for bionic vision without brain surgery. Paris-based Pixium Vision is conducting European and U.S. feasibility trials to see if its Prima system can help patients with age-related macular degeneration, a much more common condition than retinitis pigmentosa.

Daniel Palanker, a professor of ophthalmology at Stanford University who licensed his technology to Pixium, says the Prima implant is smaller, simpler, and cheaper than the Argus II. But he argues that Prima’s superior image resolution has the potential to make Pixium Vision a success. “If you provide excellent vision, there will be lots of patients,” he tells Spectrum. “If you provide crappy vision, there will be very few.”

Some clinicians involved in the Argus II work are trying to salvage what they can from the technology. Gislin Dagnelie, an associate professor of ophthalmology at Johns Hopkins University School of Medicine, has set up a network of clinicians who are still working with Argus II patients. The researchers are experimenting with a thermal camera to help users see faces, a stereo camera to filter out the background, and AI-powered object recognition. These upgrades are unlikely to result in commercial hardware today but could help future vision prostheses.

The writers have carefully balanced this piece so it is not an outright condemnation of the companies (Second Sight and Nano Precision), from the February 15, 2022 IEEE Spectrum article,

Failure is an inevitable part of innovation. The Argus II was an innovative technology, and progress made by Second Sight may pave the way for other companies that are developing bionic vision systems. But for people considering such an implant in the future, the cautionary tale of Argus patients left in the lurch may make a tough decision even tougher. Should they take a chance on a novel technology? If they do get an implant and find that it helps them navigate the world, should they allow themselves to depend upon it?

Abandoning the Argus II technology—and the people who use it—might have made short-term financial sense for Second Sight, but it’s a decision that could come back to bite the merged company if it does decide to commercialize a brain implant, believes Doerr.

For anyone curious about retinal implant technology (specifically the Argus II), I have a description in a June 30, 2015 posting.

Speculations and hopes for neuroprosthetics

The field of neuroprosthetics is very active. Dr Arthur Saniotis and Prof Maciej Henneberg have written an article where they speculate about the possibilities of a neuroprosthetic that may one day merge with neurons in a February 21, 2022 Nanowerk Spotlight article,

For over a generation several types of medical neuroprosthetics have been developed, which have improved the lives of thousands of individuals. For instance, cochlear implants have restored functional hearing in individuals with severe hearing impairment.

Further advances in motor neuroprosthetics are attempting to restore motor functions in tetraplegic, limb loss and brain stem stroke paralysis subjects.

Currently, scientists are working on various kinds of brain/machine interfaces [BMI] in order to restore movement and partial sensory function. One such device is the ‘Ipsihand’ that enables movement of a paralyzed hand. The device works by detecting the recipient’s intention in the form of electrical signals, thereby triggering hand movement.

Another recent development is the 12 month BMI gait neurohabilitation program that uses a visual-tactile feedback system in combination with a physical exoskeleton and EEG operated AI actuators while walking. This program has been tried on eight patients with reported improvements in lower limb movement and somatic sensation.

Surgically placed electrode implants have also reduced tremor symptoms in individuals with Parkinson’s disease.

Although neuroprosthetics have provided various benefits they do have their problems. Firstly, electrode implants to the brain are prone to degradation, necessitating new implants after a few years. Secondly, as in any kind of surgery, implanted electrodes can cause post-operative infection and glial scarring. Furthermore, one study showed that the neurobiological efficacy of an implant is dependent on the rate of speed of its insertion.

But what if humans designed a neuroprosthetic, which could bypass the medical glitches of invasive neuroprosthetics? However, instead of connecting devices to neural networks, this neuroprosthetic would directly merge with neurons – a novel step. Such a neuroprosthetic could radically optimize treatments for neurodegenerative disorders and brain injuries, and possibly cognitive enhancement [emphasis mine].

A team of three international scientists has recently designed a nanobased neuroprosthetic, which was published in Frontiers in Neuroscience (“Integration of Nanobots Into Neural Circuits As a Future Therapy for Treating Neurodegenerative Disorders“). [open access paper published in 2018]

An interesting feature of their nanobot neuroprosthetic is that it has been inspired from nature by way of endomyccorhizae – a type of plant/fungus symbiosis, which is over four hundred million years old. During endomyccorhizae, fungi use numerous threadlike projections called mycelium that penetrate plant roots, forming colossal underground networks with nearby root systems. During this process fungi take up vital nutrients while protecting plant roots from infections – a win-win relationship. Consequently, the nano-neuroprosthetic has been named ‘endomyccorhizae ligand interface’, or ‘ELI’ for short.

The Spotlight article goes on to describe how these nanobots might function. As for the possibility of cognitive enhancement, I wonder if that might come to be described as a form of ‘artificial intelligence’.

(Dr Arthur Saniotis and Prof Maciej Henneberg are both from the Department of Anthropology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences; and Biological Anthropology and Comparative Anatomy Research Unit, Adelaide Medical School, University of Adelaide. Abdul-Rahman Sawalma who’s listed as an author on the 2018 paper is from the Palestinian Neuroscience Initiative, Al-Quds University, Beit Hanina, Palestine.)

Saniotis and Henneberg’s Spotlight article presents an optimistic view of neuroprosthetics. It seems telling that they cite cochlear implants as a success story when it is viewed by many as ethically fraught (see the Cochlear implant Wikipedia entry; scroll down to ‘Criticism and controversy’).

Ethics and your implants

This is from an April 6, 2015 article by Luc Henry on technologist.eu,

Technologist: What are the potential consequences of accepting the “augmented human” in society?

Gregor Wolbring: There are many that we might not even envision now. But let me focus on failure and obsolescence [emphasis mine], two issues that are rarely discussed. What happens when the mechanisms fails in the middle of an action? Failure has hazardous consequences, but obsolescence has psychological ones. …. The constant surgical inter­vention needed to update the hardware may not be feasible. A person might feel obsolete if she cohabits with others using a newer version.

T. Are researchers working on prosthetics sometimes disconnected from reality?

G. W. Students engaged in the development of prosthetics have to learn how to think in societal terms and develop a broader perspective. Our education system provides them with a fascination for clever solutions to technological challenges but not with tools aiming at understanding the consequences, such as whether their product might increase or decrease social justice.

Wolbring is a professor at the University of Calgary’s Cumming School of Medicine (profile page) who writes on social issues to do with human enhancement/ augmentation. As well,

Some of his areas of engagement are: ability studies including governance of ability expectations, disability studies, governance of emerging and existing sciences and technologies (e.g. nanoscale science and technology, molecular manufacturing, aging, longevity and immortality, cognitive sciences, neuromorphic engineering, genetics, synthetic biology, robotics, artificial intelligence, automatization, brain machine interfaces, sensors), impact of science and technology on marginalized populations, especially people with disabilities he governance of bodily enhancement, sustainability issues, EcoHealth, resilience, ethics issues, health policy issues, human rights and sport.

He also maintains his own website here.

Not just startups

I’d classify Second Sight as a tech startup company and they have a high rate of failure, which may not have been clear to the patients who had the implants. Clinical trials can present problems too as this excerpt from my September 17, 2020 posting notes,

This October 31, 2017 article by Emily Underwood for Science was revelatory,

“In 2003, neurologist Helen Mayberg of Emory University in Atlanta began to test a bold, experimental treatment for people with severe depression, which involved implanting metal electrodes deep in the brain in a region called area 25 [emphases mine]. The initial data were promising; eventually, they convinced a device company, St. Jude Medical in Saint Paul, to sponsor a 200-person clinical trial dubbed BROADEN.

This month [October 2017], however, Lancet Psychiatry reported the first published data on the trial’s failure. The study stopped recruiting participants in 2012, after a 6-month study in 90 people failed to show statistically significant improvements between those receiving active stimulation and a control group, in which the device was implanted but switched off.

… a tricky dilemma for companies and research teams involved in deep brain stimulation (DBS) research: If trial participants want to keep their implants [emphases mine], who will take responsibility—and pay—for their ongoing care? And participants in last week’s meeting said it underscores the need for the growing corps of DBS researchers to think long-term about their planned studies.”

Symbiosis can be another consequence, as mentioned in my September 17, 2020 posting,

From a July 24, 2019 article by Liam Drew for Nature Outlook: The brain,

“It becomes part of you,” Patient 6 said, describing the technology that enabled her, after 45 years of severe epilepsy, to halt her disabling seizures. Electrodes had been implanted on the surface of her brain that would send a signal to a hand-held device when they detected signs of impending epileptic activity. On hearing a warning from the device, Patient 6 knew to take a dose of medication to halt the coming seizure.

“You grow gradually into it and get used to it, so it then becomes a part of every day,” she told Frederic Gilbert, an ethicist who studies brain–computer interfaces (BCIs) at the University of Tasmania in Hobart, Australia. “It became me,” she said. [emphasis mine]

Symbiosis is a term, borrowed from ecology, that means an intimate co-existence of two species for mutual advantage. As technologists work towards directly connecting the human brain to computers, it is increasingly being used to describe humans’ potential relationship with artificial intelligence. [emphasis mine]

It’s complicated

For a lot of people these devices are or could be life-changing. At the same time, there are a number of different issues related to implants/prosthetics; the following is not an exhaustive list. As Wolbring notes, issues that we can’t begin to imagine now are likely to emerge as these medical advances become more ubiquitous.

Ability/disability?

Assistive technologies are almost always portrayed as helpful. For example, a cochlear implant gives people without hearing the ability to hear. The assumption is that this is always a good thing—unless you’re a deaf person who wants to define the problem a little differently. Who gets to decide what is good and ‘normal’ and what is desirable?

While the cochlear implant is the most extreme example I can think of, there are variations of these questions throughout the ‘disability’ communities.

Also, as Wolbring notes in his interview with the Technologist.eu, the education system tends to favour technological solutions which don’t take social issues into account. Wolbring cites social justice issues when he mentions failure and obsolescence.

Technical failures and obsolescence

The story, excerpted earlier in this posting, opened with a striking example of a technical failure at an awkward moment; a blind woman depending on her retinal implant loses all sight as she maneuvers through a subway station in New York City.

Aside from being an awful way to find out the company supplying and supporting your implant is in serious financial trouble and can’t offer assistance or repair, the failure offers a preview of what could happen as implants and prosthetics become more commonly used.

Keeping up/fomo (fear of missing out)/obsolescence

It used to be called ‘keeping up with the Joneses, it’s the practice of comparing yourself and your worldly goods to someone else(‘s) and then trying to equal what they have or do better. Usually, people want to have more and better than the mythical Joneses.

These days, the phenomenon (which has been expanded to include social networking) is better known as ‘fomo’ or fear of missing out (see the Fear of missing out Wikipedia entry).

Whatever you want to call it, humanity’s competitive nature can be seen where technology is concerned. When I worked in technology companies, I noticed that hardware and software were sometimes purchased for features that were effectively useless to us. But, not upgrading to a newer version was unthinkable.

Call it fomo or ‘keeping up with the Joneses’, it’s a powerful force and when people (and even companies) miss out or can’t keep up, it can lead to a sense of inferiority in the same way that having an obsolete implant or prosthetic could.

Social consequences

Could there be a neural implant/neuroprosthetic divide? There is already a digital divide (from its Wikipedia entry),

The digital divide is a gap between those who have access to new technology and those who do not … people without access to the Internet and other ICTs [information and communication technologies] are at a socio-economic disadvantage because they are unable or less able to find and apply for jobs, shop and sell online, participate democratically, or research and learn.

After reading Wolbring’s comments, it’s not hard to imagine a neural implant/neuroprosthetic divide with its attendant psychological and social consequences.

What kind of human am I?

There are other issues as noted in my September 17, 2020 posting. I’ve already mentioned ‘patient 6’, the woman who developed a symbiotic relationship with her brain/computer interface. This is how the relationship ended,

… He [Frederic Gilbert, ethicist] is now preparing a follow-up report on Patient 6. The company that implanted the device in her brain to help free her from seizures went bankrupt. The device had to be removed.

… Patient 6 cried as she told Gilbert about losing the device. … “I lost myself,” she said.

“It was more than a device,” Gilbert says. “The company owned the existence of this new person.”

Above human

The possibility that implants will not merely restore or endow someone with ‘standard’ sight or hearing or motion or … but will augment or improve on nature was broached in this May 2, 2013 posting, More than human—a bionic ear that extends hearing beyond the usual frequencies and is one of many in the ‘Human Enhancement’ category on this blog.

More recently, Hugh Herr, an Associate Professor at the Massachusetts Institute of Technology (MIT), leader of the Biomechatronics research group at MIT’s Media Lab, a double amputee, and prosthetic enthusiast, starred in the recent (February 23, 2022) broadcast of ‘Augmented‘ on the Public Broadcasting Service (PBS) science programme, Nova.

I found ‘Augmented’ a little offputting as it gave every indication of being an advertisement for Herr’s work in the form of a hero’s journey. I was not able to watch more than 10 mins. This preview gives you a pretty good idea of what it was like although the part in ‘Augmented, where he says he’d like to be a cyborg hasn’t been included,

At a guess, there were a few talking heads (taking up from 10%-20% of the running time) who provided some cautionary words to counterbalance the enthusiasm in the rest of the programme. It’s a standard approach designed to give the impression that both sides of a question are being recognized. The cautionary material is usually inserted past the 1/2 way mark while leaving several minutes at the end for returning to the more optimistic material.

In a February 2, 2010 posting I have excerpts from an article featuring quotes from Herr that I still find startling,

Written by Paul Hochman for Fast Company, Bionic Legs, iLimbs, and Other Super-Human Prostheses [ETA March 23, 2022: an updated version of the article is now on Genius.com] delves further into the world where people may be willing to trade a healthy limb for a prosthetic. From the article,

There are many advantages to having your leg amputated.

Pedicure costs drop 50% overnight. A pair of socks lasts twice as long. But Hugh Herr, the director of the Biomechatronics Group at the MIT Media Lab, goes a step further. “It’s actually unfair,” Herr says about amputees’ advantages over the able-bodied. “As tech advancements in prosthetics come along, amputees can exploit those improvements. They can get upgrades. A person with a natural body can’t.”

Herr is not the only one who favours prosthetics (also from the Hochman article),

This influx of R&D cash, combined with breakthroughs in materials science and processor speed, has had a striking visual and social result: an emblem of hurt and loss has become a paradigm of the sleek, modern, and powerful. Which is why Michael Bailey, a 24-year-old student in Duluth, Georgia, is looking forward to the day when he can amputate the last two fingers on his left hand.

“I don’t think I would have said this if it had never happened,” says Bailey, referring to the accident that tore off his pinkie, ring, and middle fingers. “But I told Touch Bionics I’d cut the rest of my hand off if I could make all five of my fingers robotic.”

But Bailey is most surprised by his own reaction. “When I’m wearing it, I do feel different: I feel stronger. As weird as that sounds, having a piece of machinery incorporated into your body, as a part of you, well, it makes you feel above human.[emphasis mine] It’s a very powerful thing.”

My September 17, 2020 posting touches on more ethical and social issues including some of those surrounding consumer neurotechnologies or brain-computer interfaces (BCI). Unfortunately, I don’t have space for these issues here.

As for Paul Hochman’s article, Bionic Legs, iLimbs, and Other Super-Human Prostheses, now on Genius.com, it has been updated.

Money makes the world go around

Money and business practices have been indirectly referenced (for the most part) up to now in this posting. The February 15, 2022 IEEE Spectrum article and Hochman’s article, Bionic Legs, iLimbs, and Other Super-Human Prostheses, cover two aspects of the money angle.

In the IEEE Spectrum article, a tech start-up company, Second Sight, ran into financial trouble and is acquired by a company that has no plans to develop Second Sight’s core technology. The people implanted with the Argus II technology have been stranded as were ‘patient 6’ and others participating in the clinical trial described in the July 24, 2019 article by Liam Drew for Nature Outlook: The brain mentioned earlier in this posting.

I don’t know anything about the business bankruptcy mentioned in the Drew article but one of the business problems described in the IEEE Spectrum article suggests that Second Sight was founded before answering a basic question, “What is the market size for this product?”

On 18 July 2019, Second Sight sent Argus patients a letter saying it would be phasing out the retinal implant technology to clear the way for the development of its next-generation brain implant for blindness, Orion, which had begun a clinical trial with six patients the previous year. …

“The leadership at the time didn’t believe they could make [the Argus retinal implant] part of the business profitable,” Greenberg [Robert Greenberg, Second Sight co-founder] says. “I understood the decision, because I think the size of the market turned out to be smaller than we had thought.”

….

The question of whether a medical procedure or medicine can be profitable (or should the question be sufficiently profitable?) was referenced in my April 26, 2019 posting in the context of gene editing and personalized medicine

Edward Abrahams, president of the Personalized Medicine Coalition (US-based), advocates for personalized medicine while noting in passing, market forces as represented by Goldman Sachs in his May 23, 2018 piece for statnews.com (Note: A link has been removed),

Goldman Sachs, for example, issued a report titled “The Genome Revolution.” It argues that while “genome medicine” offers “tremendous value for patients and society,” curing patients may not be “a sustainable business model.” [emphasis mine] The analysis underlines that the health system is not set up to reap the benefits of new scientific discoveries and technologies. Just as we are on the precipice of an era in which gene therapies, gene-editing, and immunotherapies promise to address the root causes of disease, Goldman Sachs says that these therapies have a “very different outlook with regard to recurring revenue versus chronic therapies.”

The ‘Glybera’ story in my July 4, 2019 posting (scroll down about 40% of the way) highlights the issue with “recurring revenue versus chronic therapies,”

Kelly Crowe in a November 17, 2018 article for the CBC (Canadian Broadcasting Corporation) news writes about Glybera,

It is one of this country’s great scientific achievements.

“The first drug ever approved that can fix a faulty gene.

It’s called Glybera, and it can treat a painful and potentially deadly genetic disorder with a single dose — a genuine made-in-Canada medical breakthrough.

But most Canadians have never heard of it.

Here’s my summary (from the July 4, 2019 posting),

It cost $1M for a single treatment and that single treatment is good for at least 10 years.

Pharmaceutical companies make their money from repeated use of their medicaments and Glybera required only one treatment so the company priced it according to how much they would have gotten for repeated use, $100,000 per year over a 10 year period. The company was not able to persuade governments and/or individuals to pay the cost

In the end, 31 people got the treatment, most of them received it for free through clinical trials.

For rich people only?

Megan Devlin’s March 8, 2022 article for the Daily Hive announces a major research investment into medical research (Note: A link has been removed),

Vancouver [Canada] billionaire Chip Wilson revealed Tuesday [March 8, 2022] that he has a rare genetic condition that causes his muscles to waste away, and announced he’s spending $100 million on research to find a cure.

His condition is called facio-scapulo-humeral muscular dystrophy, or FSHD for short. It progresses rapidly in some people and more slowly in others, but is characterized by progressive muscle weakness starting the the face, the neck, shoulders, and later the lower body.

“I’m out for survival of my own life,” Wilson said.

“I also have the resources to do something about this which affects so many people in the world.”

Wilson hopes the $100 million will produce a cure or muscle-regenerating treatment by 2027.

“This could be one of the biggest discoveries of all time, for humankind,” Wilson said. “Most people lose muscle, they fall, and they die. If we can keep muscle as we age this can be a longevity drug like we’ve never seen before.”

According to rarediseases.org, FSHD affects between four and 10 people out of every 100,000 [emphasis mine], Right now, therapies are limited to exercise and pain management. There is no way to stall or reverse the disease’s course.

Wilson is best known for founding athleisure clothing company Lululemon. He also owns the most expensive home in British Columbia, a $73 million mansion in Vancouver’s Kitsilano neighbourhood.

Let’s see what the numbers add up to,

4 – 10 people out of 100,000

40 – 100 people out of 1M

1200 – 3,000 people out of 30M (let’s say this is Canada’s population)\

12,000 – 30,000 people out of 300M (let’s say this is the US’s population)

42,000 – 105,000 out of 1.115B (let’s say this is China’s population)

The rough total comes to 55,200 to 138,000 people between three countries with a combined population total of 1.445B. Given how business currently operates, it seems unlikely that any company will want to offer Wilson’s hoped for medical therapy although he and possibly others may benefit from a clinical trial.

Should profit or wealth be considerations?

The stories about the patients with the implants and the patients who need Glybera are heartbreaking and point to a question not often asked when medical therapies and medications are developed. Is the profit model the best choice and, if so, how much profit?

I have no answer to that question but I wish it was asked by medical researchers and policy makers.

As for wealthy people dictating the direction for medical research, I don’t have answers there either. I hope the research will yield applications and/or valuable information for more than Wilson’s disease.

It’s his money after all

Wilson calls his new venture, SolveFSHD. It doesn’t seem to be affiliated with any university or biomedical science organization and it’s not clear how the money will be awarded (no programmes, no application procedure, no panel of experts). There are three people on the team, Eva R. Chin, scientist and executive director, Chip Wilson, SolveFSHD founder/funder, and FSHD patient, and Neil Camarta, engineer, executive (fossil fuels and clean energy), and FSHD patient. There’s also a Twitter feed (presumably for the latest updates): https://twitter.com/SOLVEFSHD.

Perhaps unrelated but intriguing is news about a proposed new building in Kenneth Chan’s March 31, 2022 article for the Daily Hive,

Low Tide Properties, the real estate arm of Lululemon founder Chip Wilson [emphasis mine], has submitted a new development permit application to build a 148-ft-tall, eight-storey, mixed-use commercial building in the False Creek Flats of Vancouver.

The proposal, designed by local architectural firm Musson Cattell Mackey Partnership, calls for 236,000 sq ft of total floor area, including 105,000 sq ft of general office space, 102,000 sq ft of laboratory space [emphasis mine], and 5,000 sq ft of ground-level retail space. An outdoor amenity space for building workers will be provided on the rooftop.

[next door] The 2001-built, five-storey building at 1618 Station Street immediately to the west of the development site is also owned by Low Tide Properties [emphasis mine]. The Ferguson, the name of the existing building, contains about 79,000 sq ft of total floor area, including 47,000 sq ft of laboratory space and 32,000 sq ft of general office space. Biotechnology company Stemcell technologies [STEMCELL] Technologies] is the anchor tenant [emphasis mine].

I wonder if this proposed new building will house SolveFSHD and perhaps other FSHD-focused enterprises. The proximity of STEMCELL Technologies could be quite convenient. In any event, $100M will buy a lot (pun intended).

The end

Issues I’ve described here in the context of neural implants/neuroprosthetics and cutting edge medical advances are standard problems not specific to these technologies/treatments:

  • What happens when the technology fails (hopefully not at a critical moment)?
  • What happens when your supplier goes out of business or discontinues the products you purchase from them?
  • How much does it cost?
  • Who can afford the treatment/product? Will it only be for rich people?
  • Will this technology/procedure/etc. exacerbate or create new social tensions between social classes, cultural groups, religious groups, races, etc.?

Of course, having your neural implant fail suddenly in the middle of a New York City subway station seems a substantively different experience than having your car break down on the road.

There are, of course, there are the issues we can’t yet envision (as Wolbring notes) and there are issues such as symbiotic relationships with our implants and/or feeling that you are “above human.” Whether symbiosis and ‘implant/prosthetic superiority’ will affect more than a small number of people or become major issues is still to be determined.

There’s a lot to be optimistic about where new medical research and advances are concerned but I would like to see more thoughtful coverage in the media (e.g., news programmes and documentaries like ‘Augmented’) and more thoughtful comments from medical researchers.

Of course, the biggest issue I’ve raised here is about the current business models for health care products where profit is valued over people’s health and well-being. it’s a big question and I don’t see any definitive answers but the question put me in mind of this quote (from a September 22, 2020 obituary for US Supreme Court Justice Ruth Bader Ginsburg by Irene Monroe for Curve),

Ginsburg’s advocacy for justice was unwavering and showed it, especially with each oral dissent. In another oral dissent, Ginsburg quoted a familiar Martin Luther King Jr. line, adding her coda:” ‘The arc of the universe is long, but it bends toward justice,’” but only “if there is a steadfast commitment to see the task through to completion.” …

Martin Luther King Jr. popularized and paraphrased the quote (from a January 18, 2018 article by Mychal Denzel Smith for Huffington Post),

His use of the quote is best understood by considering his source material. “The arc of the moral universe is long, but it bends toward justice” is King’s clever paraphrasing of a portion of a sermon delivered in 1853 by the abolitionist minister Theodore Parker. Born in Lexington, Massachusetts, in 1810, Parker studied at Harvard Divinity School and eventually became an influential transcendentalist and minister in the Unitarian church. In that sermon, Parker said: “I do not pretend to understand the moral universe. The arc is a long one. My eye reaches but little ways. I cannot calculate the curve and complete the figure by experience of sight. I can divine it by conscience. And from what I see I am sure it bends toward justice.”

I choose to keep faith that people will get the healthcare products they need and that all of us need to keep working at making access more fair.

Fixed: The Science/Fiction of Human Enhancement

First the news, Fixed: The Science/Fiction of Human Enhancement is going to be broadcast on KCTS 9 (PBS [Public Broadcasting Service] station for Seattle/Yakima) on Wednesday, Aug. 26, 2015 at 7 pm PDT. From the KCTS 9 schedule,

From botox to bionic limbs, the human body is more “upgradeable” than ever. But how much of it can we alter and still be human? What do we gain or lose in the process? Award-winning documentary, Fixed: The Science/Fiction of Human Enhancement, explores the social impact of human biotechnologies. Haunting and humorous, poignant and political, Fixed rethinks “disability” and “normalcy” by exploring technologies that promise to change our bodies and minds forever.

This 2013 documentary has a predecessor titled ‘Fixed’, which I wrote about in an August 3, 2010 posting. The director for both ‘Fixeds’ is Regan Brashear.

It seems the latest version of Fixed builds on the themes present in the first, while integrating the latest scientific work (to 2013) in the field of human enhancement (from my August 3, 2010 posting),

As for the film, I found this at the University of California, Santa Cruz,

Fixed is a video documentary that explores the burgeoning field of “human enhancement” technologies from the perspective of individuals with disabilities. Fixed uses the current debates surrounding human enhancement technologies (i.e. bionic limbs, brain machine interfaces, prenatal screening technologies such as PGD or pre-implantation genetic diagnosis, etc.) to tackle larger questions about disability, inequality, and citizenship. This documentary asks the question, “Will these technologies ‘liberate’ humanity, or will they create even more inequality?”

You can find out more about the 2013 Fixed on its website or Facebook page (they list opportunities in the US, in Canada, and internationally to see the documentary). There is also a listing of PBS broadcasts available from the Fixed: The Science/Fiction of Human Enhancement Press page.

I recognized two names from the cast list on the Internet Movie Database (IMDB) page for Fixed: The Science/Fiction of Human Enhancement, Gregor Wolbring (he also appeared in the first ‘Fixed’) and Hugh Herr.

Gregor has been mentioned here a few times in connection with human enhancement. A Canadian professor at the University of Calgary, he’s active in the field of bioethics and you can find out more about Gregor and his work here.

Hugh Herr was first mentioned here in a January 30, 2013 posting titled: The ultimate DIY: ‘How to build a robotic man’ on BBC 4. He is a robotocist at the Massachusetts Institute of Technology (MIT).

The two men offering contrasting perspectives, Gregor Wolbring, ‘we should re-examine the notion that some people are impaired and need to be fixed’,  and Hugh Herr, ‘we will eliminate all forms of impairment’. Hopefully, the 2013 documentary has managed to present more of the nuances than I have.

Printing food, changing prostheses, and talking with Google (Larry Page) at TED 2014′s Session 6: Wired

I’m covering two speakers and an interview from this session. First, Avi Reichental, CEO (Chief Executive Officer) 3D Sytems, from his TED biography (Note: A link has been removed),

At 3D Systems, Avi Reichental is helping to imagine a future where 3D scanning-and-printing is an everyday act, and food, clothing, objects are routinely output at home.

Lately, he’s been demo-ing the Cube, a tabletop 3D printer that can print a basketball-sized object, and the ChefJet, a food-grade machine that prints in sugar and chocolate. His company is also rolling out consumer-grade 3D scanning cameras that clip to a tablet to capture three-dimensional objects for printing out later. He’s an instructor at Singularity University (watch his 4-minute intro to 3D printing).

Reichental started by talking about his grandfather, a cobbler who died in the Holocaust and whom he’d never met. Nonetheless, his grandfather had inspired him to be a maker of things in a society where craftsmanship and crafting atrophied until recently with the rise of ‘maker’ culture and 3D printing.

There were a number of items on the stage, shoes, a cake, a guitar and more, all of which had been 3D printed. Reichental’s shoes had also been produced on a 3D printer. If I understand his dream properly, it is to enable everyone to make what they need more cheaply and better.

Next, Hugh Herr, bionics designer, from his TED biography,

Hugh Herr directs the Biomechatronics research group at the MIT Media Lab, where he is pioneering a new class of biohybrid smart prostheses and exoskeletons to improve the quality of life for thousands of people with physical challenges. A computer-controlled prosthesis called the Rheo Knee, for instance, is outfitted with a microprocessor that continually senses the joint’s position and the loads applied to the limb. A powered ankle-foot prosthesis called the BiOM emulates the action of a biological leg to create a natural gait, allowing amputees to walk with normal levels of speed and metabolism as if their legs were biological.

Herr is the founder and chief technology officer of BiOM Inc., which markets the BiOM as the first in a series of products that will emulate or even augment physiological function through electromechanical replacement. You can call it (as they do) “personal bionics.”

Herr walked on his two bionic limbs onto the TED stage. He not only researches and works in the field of bionics, he lives it. His name was mentioned in a previous presentation by David Sengeh (can be found in my March 17, 2014 posting), a 2014 TED Fellow.

Herr talked about biomimcry, i.e., following nature’s lead in design but he also suggested that design is driving (affecting) nature.  If I understand him rightly, he was referencing some of the work with proteins, ligands, etc. and creating devices that are not what we would consider biological or natural as we have tended to use the term.

His talk contrasted somewhat with Reichental’s as Herr wants to remove the artisanal approach to developing prosthetics and replacing the artisanal with data-driven strategies. Herr covered the mechanical, the dynamic, and the electrical as applied to bionic limbs. I think the term prosthetic is being applied the older, artisanal limbs as opposed to these mechanical, electrical, dynamic marvels known as bionic limbs.

The mechanical aspect has to do with figuring out how your specific limbs are formed and used and getting precise measurements (with robotic tools) because everyone is a little bit different. The dynamic aspect, also highly individual, is how your muscles work. For example, standing still, walking, etc. all require dynamic responses from your muscles. Finally, there’s the integration with the nervous system so you can feel your limb.

Herr shows a few videos including one of a woman who lost part of her leg in last year’s Boston Marathon bombing (April 15, 2013). A ballroom dancer, Herr invites her to the stage so she can perform in front of the TED 2014 audience. She got a standing ovation.

In the midst of session 6, there was an interview conducted by Charlie Rose (US television presenter) with Larry Page, a co-founder of Google.

Very briefly, I was mildly relieved (although I’m not convinced) to hear that Page is devoted to the notion that search is important. I’ve been concerned about the Google search results I get. Those results seem less rich and interesting than they were a few years ago. I attribute the situation to the chase for advertising dollars and a decreasing interest in ‘search’ as the company expands with initiatives such as ‘Google glass’, artificial intelligence, and pursues other interests distinct from what had been the company’s core focus.

I didn’t find much else of interest. Larry Page wants to help people and he’s interested in artificial intelligence and transportation. His perspective seemed a bit simplistic (technology will solve our problems) but perhaps that was for the benefit of people like me. I suspect one of a speaker’s challenges at TED is finding the right level. Certainly, I’ve experienced difficulties with some of the more technical presentations.

One more observation, there was no mention of a current scandal at Google profiled in the April 2014 issue of Vanity Fair, (by Vanessa Grigoriadis)

 O.K., Glass: Make Google Eyes

The story behind Google co-founder Sergey Brin’s liaison with Google Glass marketing manager Amanda Rosenberg—and his split from his wife, genetic-testing entrepreneur Anne Wojcicki— has a decidedly futuristic edge. But, as Vanessa Grigoriadis reports, the drama leaves Silicon Valley debating emotional issues, from office romance to fear of mortality.

Given that Page agreed to be on the TED stage in the last 10 days, this appearance seems like an attempt at damage control especially with the mention of Brin who had his picture taken with the telepresent Ed Snowden on Tuesday, March 18, 2014 at TED 2014.

The ultimate DIY: ‘How to build a robotic man’ on BBC 4

British Broadcasting Corporation’s Channel 4 (BBC 4) will be telecasting the ultimate do-it-yourself (DIY) project, How to build a bionic man on Feb. 7, 2013, 9 pm GMT. Corinne Burns in a Jan. 30, 2013 posting for the Guardian science blogs describes the documentary (Note: Links have been removed),

Created by Darlow Smithson Productions (DSP, the TV company behind Touching The Void and Richard Hammond’s Engineering Connections), with the help of robotics experts Shadow Robot Company, the bionic man was conceived as a literal response to the question: how close is bionic technology is to catching up with – and even exceeding – the capabilities of the human body?

DSP got in touch with Dr Bertolt Meyer, a charismatic young researcher from Zurich University and himself a lifelong user of prosthetic technology, and invited him to, essentially, rebuild himself in bionic form. The result can be seen in How to Build a Bionic Man, to be broadcast on Channel 4 on 7 February. The Bionic Man himself will then reside in the Science Museum’s Who Am I? gallery from 7 February until 11 March.

Richard Walker (left), chief roboticist, and Dr Bertolt Meyer (right) at the Body Lab. On the table is an iWalk BiOM ankle. Photograph: Channel 4  [downloaded from http://www.guardian.co.uk/science/blog/2013/jan/30/build-bionic-man]

Richard Walker (left), chief roboticist, and Dr Bertolt Meyer (right) at the Body Lab. On the table is an iWalk BiOM ankle. Photograph: Channel 4 [downloaded from http://www.guardian.co.uk/science/blog/2013/jan/30/build-bionic-man]

Burns goes on to discuss some of the issues raised by the increasing sophistication of prosthetics (Note: Links have been removed),

The engineering behind modern prosthetics is certainly awe-inspiring. The iLimb Ultra, of which Bertolt is a user, is part of the new class of myoelectric prosthetics. These custom-made devices function by placing electrical sensors directly in contact with the skin. These sensors pick up the signals generated by muscular movements in the residual limb – signals that are then translated by software into natural, intuitive movement in the prosthetic limb.

We all know about prosthetic limbs, even if many of us are not aware of just how sophisticated they now are. Less familiar, though, is the idea of bionic organs. Far removed from the iron lung of yore, these new fully integrated artificial body parts are designed to plug directly into our own metabolism – in effect, they are not within us, they become us. They’re the ultimate in biomimicry.

It’s one thing to use a bionic organ to replace lost function. But in a future world where we could, feasibly, replace virtually all of our body, will we blur the boundaries of artificial and natural to an extent that we have to recalibrate our definition of self and non-self? That’s especially pertinent when we consider the reality of neural prosthetics, like the “memory chips” developed by Dr Theodore Berger. Instinctively, many of us are uncomfortable with brain implants – but should we be? And will this discomfort be reduced if we broaden our definition of self?

Bertolt himself is pleased with the increasing normalisation, and even “coolness”, of prosthetics. But he expresses caution about the potential for elective use of such technology – would we ever choose to remove a healthy body part, in order to replace it with a stronger, better prosthetic?

Burns’ posting isn’t the only place where these discussion points and others related to human enhancement and robotic technologies are being raised, in a Jan. 18, 2013 posting I mentioned *a television advertisement for a new smartphone that ‘upgrades your brain’ that ‘normalises’ the idea of brain implants and other enhancements for everybody. As well, The Economist recently featured an article, You, robot? in its September 1st – 7th, 2012 issue about the European Union’s RoboLaw Project,

SPEAKING at a conference organised by The Economist earlier this year [2012], Hugh Herr, a roboticist at the Massachusetts Institute of Technology, described disabilities as conditions that persist “because of poor technology” and made the bold claim that during the 21st century disability would be largely eliminated. What gave his words added force was that half way through his speech, after ten minutes of strolling around the stage, he unexpectedly pulled up his trouser legs to reveal his bionic legs, and then danced a little jig. In future, he suggested, people might choose to replace an arthritic, painful limb with a fully functional robotic one. “Why wouldn’t you replace it?” he asked. “We’re going to see a lot of unusual situations like that.”

It is precisely to consider these sorts of situations, and the legal and ethical conundrums they will pose, that a new research project was launched in March. Is a prosthetic legally part of your body? When is it appropriate to amputate a limb and replace it with a robotic one? What are the legal rights of a person with “locked in” syndrome who communicates via a brain-computer interface? Do brain implants and body-enhancement devices require changes to the definition of disability? The RoboLaw project is an effort to anticipate such quandaries and work out where and how legal frameworks might need to be changed as the technology of bionics and neural interfaces improves. Funded to the tune of €1.9m ($2.3m), of which €1.4m comes from the European Commission, it brings together experts from engineering, law, regulation, philosophy and human enhancement.

There have been some recent legal challenges as to what constitutes one’s body (from The Economist article, You, robot?),

If you are dependent on a robotic wheelchair for mobility, for example, does the wheelchair count as part of your body? Linda MacDonald Glenn, an American lawyer and bioethicist, thinks it does. Ms Glenn (who is not involved in the RoboLaw project) persuaded an initially sceptical insurance firm that a “mobility assistance device” damaged by airline staff was more than her client’s personal property, it was an extension of his physical body. The airline settled out of court.

RoboLaw is a European Union Framework Programme 7-funded two year project, which started in 2012. There is a conference to be held in the Netherlands, April 23 – 24, 2013, from the RoboLaw home page,

RoboLaw Authors Workshop and Volume on ‘Opportunities and risks of robotics in relation to human values’

23-24 April 2013, Tilburg University, Tilburg (The Netherlands)

Call for paper and participation. Robotic technologies, taken to encompass anything from ‘traditional’ robots to emerging technologies in the field of biomedical research, such as nanotechnologies, bionics, and neural interfaces, as well as innovative biomedical applications, such as biomechatronic prostheses, hybrid bionic systems and bio- mechatronic components for sensory and motor augmentation, will have a profound impact on our lives. They may also affect human values, such as privacy, autonomy, bodily integrity, health, etc. In this workshop, we will focus on the impact of new technologies, and particularly robotics, on fundamental rights and human values. …

Important dates
Before 1 January 2013: Send an email to Ronald Leenes confirming your attendance, expressing your intention to either submit a paper or act as a commentator/reviewer.
Before 1 February: Send a 300 word abstract of the intended paper to Ronald Leenes
Before 8 February: Notification of acceptance.
Before 1 March: If your abstract has been accepted, send a draft of your full paper in PDF format to Ronald Leenes
Before 5 March: Circulation of papers
23-24 April 2013: Workshop
10 May: Selected final papers to be handed in.

According to the schedule, it’s a bit late to start the process for submitting an abstract but it never hurts to try.

Canadian academic, Gregor Wolbring, assistant professor, Dept of Community Health Sciences, Program in Community Rehabilitation and Disability Studies at the University of Calgary and past president of the Canadian Disability Studies Association, offers a nuanced perspective on human enhancement issues and the term, ableism. From my Aug. 30, 2011 posting on cyborgs, eyeborgs and others,

… Gregor’s June 17, 2011 posting on the FedCan blog,

The term ableism evolved from the disabled people rights movements in the United States and Britain during the 1960s and 1970s.  It questions and highlights the prejudice and discrimination experienced by persons whose body structure and ability functioning were labelled as ‘impaired’ as sub species-typical. Ableism of this flavor is a set of beliefs, processes and practices, which favors species-typical normative body structure based abilities. It labels ‘sub-normative’ species-typical biological structures as ‘deficient’, as not able to perform as expected.

The disabled people rights discourse and disability studies scholars question the assumption of deficiency intrinsic to ‘below the norm’ labeled body abilities and the favoritism for normative species-typical body abilities. The discourse around deafness and Deaf Culture would be one example where many hearing people expect the ability to hear. This expectation leads them to see deafness as a deficiency to be treated through medical means. In contrast, many Deaf people see hearing as an irrelevant ability and do not perceive themselves as ill and in need of gaining the ability to hear. Within the disabled people rights framework ableism was set up as a term to be used like sexism and racism to highlight unjust and inequitable treatment.

Ableism is, however, much more pervasive.

Ableism based on biological structure is not limited to the species-typical/ sub species-typical dichotomy. With recent science and technology advances, and envisioned advances to come, we will see the dichotomy of people exhibiting species-typical and the so-called sub species-typical abilities labeled as impaired, and in ill health. On the other side we will see people exhibiting beyond species-typical abilities as the new expectation norm. An ableism that favours beyond species-typical abilities over species-typical and sub species-typical abilities will enable a change in meaning and scope of concepts such as health, illness, rehabilitation, disability adjusted life years, medicine, health care, and health insurance. For example, one will only be labeled as healthy if one has received the newest upgrade to one’s body – meaning one would by default be ill until one receives the upgrade.

You can find more about Gregor’s work on his University of Calgary webpage or his blog.

Finally, for anyone who wants a look at BBC 4’s ‘biionic man’,

A television company asked Dr Bertolt Meyer – who has a prosthetic arm – to rebuild himself in bionic form. Photograph: Channel 4 [downloaded from http://www.guardian.co.uk/science/blog/2013/jan/30/build-bionic-man]

A television company asked Dr Bertolt Meyer – who has a prosthetic arm – to rebuild himself in bionic form. Photograph: Channel 4 [downloaded from http://www.guardian.co.uk/science/blog/2013/jan/30/build-bionic-man]

* The articles ‘an’ was corrected to ‘a’ on July 16, 2013.

nanoBIDS; military robots from prototype to working model; prosthetics, the wave of the future?

The Nanowerk website is expanding. From their news item,

Nanowerk, the leading information provider for all areas of nanotechnologies, today added to its nanotechnology information portal a new free service for buyers and vendors of micro- and nanotechnology equipment and services. The new application, called nanoBIDS, is now available on the Nanowerk website. nanoBIDS facilitates the public posting of Requests for Proposal (RFPs) for equipment and services from procurement departments in the micro- and nanotechnologies community. nanoBIDS is open to all research organizations and companies.

I checked out the nanoBIDS page and found RFP listings from UK, US (mostly), and Germany. The earliest are dated Jan.25, 2010 so this site is just over a week old and already has two pages.

The Big Dog robot (which I posted about briefly here) is in the news again. Kit Eaton (Fast Company) whose article last October first alerted me to this device now writes that the robot is being put into production. From the article (Robocalypse Alert: Defense Contract Awarded to Scary BigDog),

The contract’s been won by maker Boston Dynamics, which has just 30 months to turn the research prototype machines into a genuine load-toting, four-legged, semi-intelligent war robot–“first walk-out” of the newly-designated LS3 is scheduled in 2012.

LS3 stands for Legged Squad Support System, and that pretty much sums up what the device is all about: It’s a semi-autonomous assistant designed to follow soldiers and Marines across the battlefield, carrying up to 400 pounds of gear and enough fuel to keep it going for 24 hours over a march of 20 miles.

They have included a video of the prototype on a beach in Thailand and as Eaton notes, the robot is “disarmingly ‘cute'” and, to me, its legs look almost human-shaped, which leads me to my next bit.

I found another article on prosthetics this morning and it’s a very good one. Written by Paul Hochman for Fast Company [ETA March 23, 2022: an updated version of the article is now on Genius.com], Bionic Legs, iLimbs, and Other Super-Human Prostheses delves further into the world where people may be willing to trade a healthy limb for a prosthetic. From the article,

There are many advantages to having your leg amputated.

Pedicure costs drop 50% overnight. A pair of socks lasts twice as long. But Hugh Herr, the director of the Biomechatronics Group at the MIT Media Lab, goes a step further. “It’s actually unfair,” Herr says about amputees’ advantages over the able-bodied. “As tech advancements in prosthetics come along, amputees can exploit those improvements. They can get upgrades. A person with a natural body can’t.”

I came across both a milder version of this sentiment and a more targeted version (able-bodied athletes worried about double amputee Oscar Pistorius’ bid to run in the Olympics rather than the Paralympics) when I wrote my four part series on human enhancement (July 22, 23, 24 & 27, 2009).

The Hochman article also goes on to discuss some of the aesthetic considerations (which I discussed in the same posting where I mentioned the BigDog robots). What Hochman does particularly well is bringing all this information together and explaining how the lure of big money (profit) is stimulating market development,

Not surprisingly, the money is following the market. MIT’s Herr cofounded a company called iWalk, which has received $10 million in venture financing to develop the PowerFoot One — what the company calls the “world’s first actively powered prosthetic ankle and foot.” Meanwhile, the Department of Veterans Affairs recently gave Brown University’s Center for Restorative and Regenerative Medicine a $7 million round of funding, on top of the $7.2 million it provided in 2004. And the Defense Advanced Research Projects Administration (DARPA) has funded Manchester, New Hampshire-based DEKA Research, which is developing the Luke, a powered prosthetic arm (named after Luke Skywalker, whose hand is hacked off by his father, Darth Vader).

This influx of R&D cash, combined with breakthroughs in materials science and processor speed, has had a striking visual and social result: an emblem of hurt and loss has become a paradigm of the sleek, modern, and powerful. Which is why Michael Bailey, a 24-year-old student in Duluth, Georgia, is looking forward to the day when he can amputate the last two fingers on his left hand.

“I don’t think I would have said this if it had never happened,” says Bailey, referring to the accident that tore off his pinkie, ring, and middle fingers. “But I told Touch Bionics I’d cut the rest of my hand off if I could make all five of my fingers robotic.”

This kind of thinking is influencing surgery such that patients are asking to have more of their bodies removed.

The article is lengthy (by internet standards) and worthwhile as it contains nuggets such as this,

But Bailey is most surprised by his own reaction. “When I’m wearing it, I do feel different: I feel stronger. As weird as that sounds, having a piece of machinery incorporated into your body, as a part of you, well, it makes you feel above human. It’s a very powerful thing.”

So the prosthetic makes him “feel above human,” interesting, eh? It leads to the next question (and a grand and philosophical one it is), what does it mean to be human? At least lately, I tend to explore that question by reading fiction.

I have been intrigued by Catherine Asaro‘s Skolian Empire series of books. The series features human beings (mostly soldiers) who have something she calls ‘biomech’  in their bodies to make them smarter, stronger, and faster. She also populates worlds with people who’ve had (thousands of years before) extensive genetic manipulation so they can better adapt to their new homeworlds. Her characters represent different opinions about the ‘biomech’ which is surgically implanted usually in adulthood and voluntarily. Asaro is a physicist who writes ‘hard’ science fiction laced with romance. She handles a great many thorny social questions in the context of this Skolian Empire that she has created where the technologies (nano, genetic engineering, etc.)  that we are exploring are a daily reality.